Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADRIAN MURPHY

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1427497551
CMS profile
489606
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,970.52

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Servier Pharmaceuticals LLC $1,970.52 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADRIAN MURPHY

NPI 1427497551 · CMS profile ID 489606

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427497551?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADRIAN MURPHY, NPI 1427497551, CMS profile ID 489606. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427497551?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ADRIAN MURPHY, NPI 1427497551, CMS profile ID 489606. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427497551?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ADRIAN MURPHY, NPI 1427497551, CMS profile ID 489606, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1427497551?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,970.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Servier Pharmaceuticals LLC $422.7306/15/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852924231 CMS
Servier Pharmaceuticals LLC $1,547.7905/20/2021 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852924229 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71.91 3
PY2021 $1,970.52 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $1,667.00 1
PY2022 Principal investigator $914.00 2
PY2021 Recipient $900.00 1
PY2021 Principal investigator $124,905.39 10
PY2020 Principal investigator $58,159.05 52
PY2019 Principal investigator $188,248.71 136

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

136 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $304.20 12/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501821
Principal investigator 1 Incyte Corporation $64.25 12/09/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501745
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,873.10 10/31/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370717
Principal investigator 1 Incyte Corporation $1,000.00 10/22/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666501813
Principal investigator 1 Incyte Corporation $650.00 10/22/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666501815
Principal investigator 1 Incyte Corporation $1,950.00 10/22/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666501817
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,436.55 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370643
Principal investigator 1 Incyte Corporation $338.00 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501819
Principal investigator 1 Incyte Corporation $338.00 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501839
Principal investigator 1 Incyte Corporation $338.00 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501841
Principal investigator 1 Incyte Corporation $338.00 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501843
Principal investigator 1 Incyte Corporation $169.00 10/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501845
Principal investigator 1 Incyte Corporation $887.00 09/27/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501807
Principal investigator 1 Halozyme Inc $704.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033255
Principal investigator 1 Halozyme Inc $162.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033257
Principal investigator 1 Halozyme Inc $1,759.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033261
Principal investigator 1 Halozyme Inc $1,407.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033263
Principal investigator 1 Halozyme Inc $4,221.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033265
Principal investigator 1 Halozyme Inc $35.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033267
Principal investigator 1 Halozyme Inc $162.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033269
Principal investigator 1 Halozyme Inc $35.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033271
Principal investigator 1 Halozyme Inc $162.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033273
Principal investigator 1 Halozyme Inc $35.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033275
Principal investigator 1 Halozyme Inc $162.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033277
Principal investigator 1 Halozyme Inc $35.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033279
Principal investigator 1 Halozyme Inc $1,055.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033283
Principal investigator 1 Halozyme Inc $1,689.00 09/04/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706033287
Principal investigator 1 Incyte Corporation $4,475.00 09/03/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501731
Principal investigator 1 Incyte Corporation $1,055.00 09/03/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501733
Principal investigator 1 Incyte Corporation $648.00 09/03/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501809
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,436.55 08/29/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370539
Principal investigator 1 Incyte Corporation $280.00 08/21/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501803
Principal investigator 1 Incyte Corporation $1,570.00 08/16/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501801
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,408.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370475
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,436.55 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370477
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,110.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370483
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,622.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370489
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,759.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370491
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,436.55 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370493
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,458.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370495
Principal investigator 1 Agios Pharmaceuticals, Inc. $1,893.82 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370497
Principal investigator 1 Agios Pharmaceuticals, Inc. $3,653.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370503
Principal investigator 1 Agios Pharmaceuticals, Inc. $150.00 08/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370509
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,414.87 07/29/2019 Non-covered Recipient Entity
Johns Hopkins University
Phase I II FIH STING Monotherapy Combination No dispute reported 06/30/2026 639756963
Principal investigator 1 Incyte Corporation $2,333.00 07/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501725
Principal investigator 1 Incyte Corporation $1,644.00 07/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501727
Principal investigator 1 Incyte Corporation $1,473.00 07/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501729
Principal investigator 1 Incyte Corporation $2,333.00 07/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501739
Principal investigator 1 Incyte Corporation $1,473.00 07/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501741
Principal investigator 1 Incyte Corporation $28.94 07/10/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501735
Principal investigator 1 Incyte Corporation $845.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475979
Principal investigator 1 Incyte Corporation $3,518.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475981
Principal investigator 1 Incyte Corporation $1,407.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475983
Principal investigator 1 Incyte Corporation $14,529.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475985
Principal investigator 1 Incyte Corporation $4,812.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475987
Principal investigator 1 Incyte Corporation $704.00 06/11/2019 Non-covered Recipient Entity
JOHNS HOPKINS MEDICINE - THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666475989
Principal investigator 1 Agios Pharmaceuticals, Inc. $4,470.05 05/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370307
Principal investigator 1 Incyte Corporation $2,700.00 05/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
GRAVITAS 309-A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease No dispute reported 06/30/2026 666501721
Principal investigator 1 Incyte Corporation $1,644.00 05/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501653
Principal investigator 1 Incyte Corporation $1,644.00 05/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501697
Principal investigator 1 Incyte Corporation $657.60 05/06/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501699
Principal investigator 1 Halozyme Inc $35.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031947
Principal investigator 1 Halozyme Inc $35.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031949
Principal investigator 1 Halozyme Inc $162.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031953
Principal investigator 1 Halozyme Inc $162.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031955
Principal investigator 1 Halozyme Inc $162.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031957
Principal investigator 1 Halozyme Inc $35.00 05/02/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706031959
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,217.44 04/30/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370201
Principal investigator 1 Incyte Corporation $1,408.00 04/25/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501645
Principal investigator 1 Incyte Corporation $9,349.00 04/25/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501651
Principal investigator 1 Incyte Corporation $4,974.00 04/25/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501687
Principal investigator 1 Incyte Corporation $972.00 04/25/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501691
Principal investigator 1 Incyte Corporation $1,644.00 04/17/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501649
Principal investigator 1 Incyte Corporation $986.40 04/17/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501695
Principal investigator 1 Incyte Corporation $53.50 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501655
Principal investigator 1 Incyte Corporation $25.70 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501657
Principal investigator 1 Incyte Corporation $21.40 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501659
Principal investigator 1 Incyte Corporation $85.60 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501661
Principal investigator 1 Incyte Corporation $25.00 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501663
Principal investigator 1 Incyte Corporation $61.75 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501665
Principal investigator 1 Incyte Corporation $10.80 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501667
Principal investigator 1 Incyte Corporation $171.20 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501669
Principal investigator 1 Incyte Corporation $28.94 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501671
Principal investigator 1 Incyte Corporation $52.12 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501673
Principal investigator 1 Incyte Corporation $26.65 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501675
Principal investigator 1 Incyte Corporation $103.60 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501677
Principal investigator 1 Incyte Corporation $15.40 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501679
Principal investigator 1 Incyte Corporation $1.25 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501681
Principal investigator 1 Incyte Corporation $24.00 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501683
Principal investigator 1 Incyte Corporation $21.40 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501701
Principal investigator 1 Incyte Corporation $21.40 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501703
Principal investigator 1 Incyte Corporation $171.20 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501705
Principal investigator 1 Incyte Corporation $10.80 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501707
Principal investigator 1 Incyte Corporation $10.80 04/08/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666501709
Principal investigator 1 Incyte Corporation $3,934.00 04/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501641
Principal investigator 1 Incyte Corporation $562.00 04/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501643
Principal investigator 1 Incyte Corporation $383.00 04/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501647
Principal investigator 1 Incyte Corporation $6,990.00 04/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501685
Principal investigator 1 Incyte Corporation $1,458.00 04/01/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501689
Principal investigator 1 Agios Pharmaceuticals, Inc. $2,873.10 03/19/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370095
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501561
Principal investigator 1 Incyte Corporation $868.80 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501563
Principal investigator 1 Incyte Corporation $1,473.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501565
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501589
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501591
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501593
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501595
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501597
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501599
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501601
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501603
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501605
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501607
Principal investigator 1 Incyte Corporation $1,644.00 03/14/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501609
Principal investigator 1 Agios Pharmaceuticals, Inc. $5,007.53 02/26/2019 Non-covered Recipient Entity
JOHNS HOPKINS HOSPITAL
STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY No dispute reported 06/30/2026 701370061
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501557
Principal investigator 1 Incyte Corporation $126.90 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501559
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501567
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501569
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501571
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501573
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501575
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501577
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501579
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501581
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501583
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501585
Principal investigator 1 Incyte Corporation $1,644.00 02/13/2019 Non-covered Recipient Entity
JOHNS HOPKINS UNIV SCHL OF MEDICINE
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666501587
Principal investigator 1 Halozyme Inc $35.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030853
Principal investigator 1 Halozyme Inc $1,055.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030855
Principal investigator 1 Halozyme Inc $1,055.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030857
Principal investigator 1 Halozyme Inc $162.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030859
Principal investigator 1 Halozyme Inc $162.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030861
Principal investigator 1 Halozyme Inc $35.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030865
Principal investigator 1 Halozyme Inc $35.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030867
Principal investigator 1 Halozyme Inc $162.00 02/01/2019 Non-covered Recipient Entity
Johns Hopkins University
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma No dispute reported 06/30/2026 706030869